0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > MS4A1

MS4A1

MS4A1 Molecule Information

Name:B-lymphocyte antigen CD20
Target Synonym:CD20?MS4A1?Membrane-spanning 4-domains subfamily A member 1?CD_antigen=CD20?B-lymphocyte antigen CD20?Leukocyte surface antigen Leu-16?Bp35?B-lymphocyte surface antigen B1
Number of Launched Drugs:20
Number of Drugs in Clinical Trials:80
Lastest Research Phase:Approved

MS4A1 Molecule Synonym Name

MS4A1,CD20,MS4A-1

MS4A1 Molecule Background

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

MS4A1 References

MS4A1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Rituximab biosimilar (Dr Reddy's Laboratories) Approved Dr Reddys Laboratories Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) Details
Rituximab IDEC-102; IDEC-C2B8; R-105; RG-105; RO-452294 Approved Biogen, Chugai, Genentech RITUXAN fda Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) GENENTECH 1997-11-26 Acute rejection in renal transplantation, Kidney disorders, Granulomatosis with polyangiitis, Chronic lymphocytic leukemia (CLL), CD20-positive follicular lymphoma, Idiopathic thrombocytopenic purpura (ITP), Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL), Microscopic polyangiitis, Non-Hodgkin B-cell lymphomas, Pemphigus vulgaris Details
Rituximab biosimilar (Hetero Drugs) Approved Hetero Drugs Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Intas Biopharmaceuticals) Approved Intas Biopharmaceuticals Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) Details
Ibritumomab tiuxetan SHL-749; IDEC-2B8-MX-DTPA; BAY86-5128; IDEC-129; IDEC-In2B8; IDEC-Y2B8,SHL749 Approved Biogen, Spectrum Pharmaceuticals, Bayer ZEVALIN fda Non-Hodgkin B-cell lymphomas SPECTRUM PHARMS 2002-02-19 Mantle cell lymphoma (MCL), Non-Hodgkin B-cell lymphomas Details
Rituximab biosimilar (Celltrion) CT-P10,CTP10; CTP-10 Approved Celltrion rituximab ema Celltrion Healthcare Hungary Kft. 2017-02-17 Granulomatosis with polyangiitis, Chronic lymphocytic leukemia (CLL), Diffuse large B cell lymphoma, Follicular lymphoma, Rheumatoid arthritis (RA), Microscopic polyangiitis Details
Rituximab biosimilar (mAbxience) mAbx-02; RTXM-83 Approved mAbxience Diffuse large B cell lymphoma Details
Rituximab biosimilar (Shanghai Henlius Biotech) HLX-01 Approved Shanghai Henlius Biotech Rituximab Injection cfda Non-Hodgkin's lymphoma (NHL) 2019-02-22 Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Probiomed) PBO-326 Approved Probiomed Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Reliance Life Sciences) R-TPR-017 Approved Reliance Life Sciences, Torrent Pharmaceuticals Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) Details
Ocrelizumab RG-1594; PRO-70769; R-1594; rhuMab 2H7; RO-4964913 ,RG1594; RG 1594 Approved Genentech, Chugai, Biogen OCREVUS fda Multiple sclerosis (MS) GENENTECH INC 2017-03-28 Multiple sclerosis (MS) Details
Rituximab biosimilar (Biocad) BCD-020 Approved Biocad Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Sandoz) GP-2013 Approved Sandoz, Kyowa Hakko Kirin rituximab ema Sandoz GmbH 2017-06-15 Granulomatosis with polyangiitis, Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL), Microscopic polyangiitis, Non-Hodgkin B-cell lymphomas Details
Rituximab biosimilar (Biosidus) Approved Biosidus Hematological cancer Details
Ofatumumab HuMax-CD2; GSK-1841157; 2F2; OMB-157,GSK1841157 Approved Genmab, Novartis, GlaxoSmithKline ARZERRA fda Chronic lymphocytic leukemia (CLL) GLAXO GRP LTD 2009-10-26 Chronic lymphocytic leukemia (CLL) Details
Rituximab biosimilar (Center of Molecular Immunology) RituxCIM Approved Center of molecular immunology, CIMAB Non-Hodgkin's lymphoma (NHL) Details
Obinutuzumab B-HH6-B-KV1-GE; RO-5072759; GA-101; R-7159; RG-7159; RG-7195 Approved Genentech, Nippon Shinyaku Pharma, Chugai GAZYVA fda Chronic lymphocytic leukemia (CLL), Follicular lymphoma GENENTECH 2013-11-01 Chronic lymphocytic leukemia (CLL), CD20-positive follicular lymphoma, Follicular lymphoma Details
Hyaluronidase/Rituximab Approved Genentech RITUXAN HYCELA fda GENENTECH INC 2017-06-22 Chronic lymphocytic leukemia (CLL), Diffuse large B cell lymphoma, Follicular lymphoma Details
Rituximab biosimilar (AryoGen Biopharma) Approved AryoGen Biopharma Wegener's granulomatosis, Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL), Microscopic polyangiitis, Chronic myeloid leukemia (CML ) Details
rituximab biosimilar (Zenotech) Approved Zenotech laboratories Non-Hodgkin's lymphoma (NHL) Details

MS4A1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) CART-20; CBM-C20.1; CBM-CD20 1;,CART 20; CBM C20.1; CBM CD20 1;,CART20; CBMC20.1; CBMCD20 1; Phase Ⅱ General Hospital of the People's Liberation Army, Cellular Biomedicine Group Leukemia, Lymphoma Details
Humanized monoclonal antibody targeting CD20 (Shanghai Pharmaceuticals Holding) B-001 Phase Ⅰ Shanghai Pharmaceuticals Holding Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) Details
64Cu-DOTA-rituximab (Stanford University) 64Cu-DOTA-Rituximab; Cu64-DOTA-rituximab; Cu-64 Rituximab; [64Cu]DOTA-rituximab Phase Ⅰ Stanford University Non-Hodgkin's lymphoma (NHL) Details
GB-4542 (Gliknik) GB-4542 Preclinical Gliknik Autoimmune diseases, Cancer Details
XmAb-13676 THG-338; XmAb-13677; XmAb-13676; XENP-13677 Phase Ⅰ Xencor, Novartis Chronic lymphocytic leukemia (CLL), B-cell lymphoma, Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Gedeon Richter) RGB-03 Phase Ⅰ Gedeon Richter, STADA Arzneimittel, Mochida Rheumatoid arthritis (RA) Details
PF-5212374 PF-5212374; CytoxB20G; TRU-015,Cytox-B20G Phase Ⅱ Emergent, Pfizer Rheumatoid arthritis (RA), Non-Hodgkin B-cell lymphomas Details
FBTA-05 Bi-20; FBTA-05 Phase Ⅱ Trion Research Lymphoblastic leukaemia, B-cell lymphoma Details
Rituximab biosimilar (Lonza/Teva Pharmaceutical Industries) TL-011 Phase Ⅲ Lonza, Teva Pharmaceutical Industries Diffuse large B cell lymphoma, Rheumatoid arthritis (RA) Details
TRS-005 TRS-005,TRS005; TRS 005 Phase Ⅰ Zhejiang Teruisi Pharmaceutical Non-Hodgkin's lymphoma (NHL) Details
H02 H-02,H02; H 02 Phase Ⅰ Shandong Xinshidai Pharmaceutical Non-Hodgkin's lymphoma (NHL) Details
Recombinant chimeric anti-CD20 monoclonal antibody (Sinocelltech) SCT-400,SCT400 Phase Ⅲ Sinocelltech, China Shijiazhuang Pharmaceutical Group/CSPC Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Lupin) Preclinical Lupin Rheumatoid arthritis (RA) Details
MB-CART20.1 (Miltenyi Biotec) Phase Ⅱ Miltenyi Biotec Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) Phase Ⅱ Hisun Pharm, Beijing Mabworks Biotech Diffuse large B cell lymphoma Details
Rituximab conjugate (BioIntegrator) CON-4619 Phase Ⅰ BioIntegrator Non-Hodgkin's lymphoma (NHL) Details
Recombinant human anti-CD20 monoclonal antibody (Sailemin Biotech) IND Filing Shenzhen Sailemin Biological Technology Unspecified Details
Pretarget lymphoma therapy (Poniard) Phase Ⅰ Poniard Pharmaceuticals Non-Hodgkin's lymphoma (NHL) Details
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) Phase Ⅰ Shanghai Institute of Biological Products hematological malignancies Details
MB-106 MB-106 Phase Ⅱ Fred Hutchinson Cancer Research Center, Mustang Bio Non-Hodgkin's lymphoma (NHL) Details
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) BAT-4306F Phase Ⅰ Bio-Thera Solutions Chronic lymphocytic leukemia (CLL), Multiple sclerosis (MS), Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) Phase Ⅱ General Hospital of the People's Liberation Army B-cell lymphoma, Leukemia Details
RG-6026 RG-6026 Phase Ⅰ Roche Follicular B cell non-Hodgkin lymphoma (FL) Details
MT-3724 MT-3724 Phase Ⅱ Molecular Partners, Banner MD Anderson Cancer Center, Molecular Templates Non-Hodgkin's lymphoma (NHL) Details
Mosunetuzumab RO-7030816; RG-7828; BTCT-4465A Phase Ⅰ Genentech, Chugai Chronic lymphocytic leukemia (CLL), B-cell lymphoma Details
TAD-011 TAD-011 Preclinical TOT Biopharm Mantle cell lymphoma (MCL), Solid tumours Details
Rituximab biosimilar (Innovent Biologics) IBI-301 Phase Ⅲ Innovent Biologics, Lilly Diffuse large B cell lymphoma Details
Rituximab biosimilar (Shenzhen Main Luck Pharmaceuticals) Phase Ⅰ Shenzhen Main Luck Pharmaceuticals Rheumatoid arthritis (RA), Lymphoma Details
HSK-III-001 HSK-III-001 Phase Ⅰ Haisco Pharmaceutical Group hematological malignancies Details
Rituximab biosimilar (Boehringer Ingelheim) BI-695500 Phase Ⅲ Boehringer Ingelheim Follicular lymphoma, Rheumatoid arthritis (RA) Details
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) Phase Ⅰ Shanghai Pharma Lymphoma Details
IGN-002 IGN-002 Phase Ⅰ ImmunoGen, The Leukemia & Lymphoma Society, Valor Biotherapeutics Non-Hodgkin's lymphoma (NHL) Details
MK-8808 MK-8808,MK8808 Phase Ⅲ Merck Sharp & Dohme Non-Hodgkin's lymphoma (NHL) Details
REGN-1979 REGN-1979 Phase Ⅰ Regeneron Pharmaceutical, Sanofi B-cell lymphoma, Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
Rituximab biosimilar (AXXO) Phase Not Specified AXXO Leukemia, Rheumatoid arthritis (RA) Details
Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) Phase Ⅱ Fred Hutchinson Cancer Research Center Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Waldenström's macroglobulinemia (WM), Follicular lymphoma, Marginal zone lymphoma, Non-Hodgkin B-cell lymphomas Details
MRG001 MRG-001,MRG001 Phase Ⅰ Shanghai Miracogen Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (JHL Biotech) JHL-1101 Phase Ⅲ JHL Biotech, Sanofi Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) Details
DI-Leu16-IL2 DI-Leu16-IL2 Phase Ⅱ Merck Serono, Alopexx Oncology, Provenance Biopharmaceuticals Non-Hodgkin's lymphoma (NHL) Details
Recombinant humanized monoclonal antibody MIL62 Phase Ⅰ Beijing Mabworks Biotech B-cell lymphoma, Chronic lymphocytic leukemia (CLL) Details
Recombinant anti-CD20 monoclonal antibody (Geneky Biotech) IND Filing Genekey Biotech (Chengdu) Rheumatoid arthritis (RA), Lymphoma Details
BVX20-CD20 antibody (Biocon/Vaccinex) BVX-20; BVX20-MAb Phase Ⅱ Biocon, Vaccinex Non-Hodgkin's lymphoma (NHL) Details
Recombinant human anti-CD20 monoclonal antibody (Zhejiang Teruisi Pharmaceutical) TRS001 Phase Ⅰ Zhejiang Teruisi Pharmaceutical Lymphoma Details
177-Lu-DOTA-rituximab (University of Basel) Phase Ⅱ University Hospital Basel Cancer Details
ACTR-707 Phase Ⅰ Unum Therapeutics Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (International Biotech Center Generium) GNR-006 Phase Ⅰ International Biotech Center Generium B-cell lymphoma Details
Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (Barbara Ann Karmanos Cancer Institute) Phase Ⅰ Barbara Ann Karmanos Cancer Institute, National Cancer Institute Lymphoma Details
Anti-CLEVER-1 antibodies (Faron Pharmaceuticals) FP-1115; FP-1302; FP-1304; FP-1305 Preclinical Faron Cancer Details
BCD-132 BCD-132,BCD 132,BCD132 Phase Ⅰ Biocad Multiple sclerosis (MS) Details
Rituximab biosimilar (Nichi-Iko Pharmaceutical/Aprogen) AP-056 BLA Filing Nichi-Iko Pharmaceutical, Aprogen Autoimmune diseases, Transplant rejection, Leukemia, Non-Hodgkin's lymphoma (NHL) Details
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase Ⅱ Southwest Hospital Chongqing Diffuse large B cell lymphoma Details
TAT-014 TAT-014,BCIA07; TAA013; TAD 011; TAT014; TOT104,BCIA-07; TAA-013; TAD-011; TAT 014; TOT-104 Preclinical TOT Biopharm Mantle cell lymphoma (MCL), Solid tumours Details
Rituximab biosimilar (Samsung) SAIT-101 Phase Ⅲ Samsung BioLogics Rheumatoid arthritis (RA) Details
PRO-131921 PRO-131921 Phase Ⅱ Genentech Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) Phase Ⅰ Medical College of Wisconsin B-cell malignancies, Cancer Details
Rituximab biosimilar (BioIntegrator) Phase Ⅰ BioIntegrator Rheumatoid arthritis (RA), Cancer Details
Rituximab biosimilar (Shanghai CP Guojian Pharmaceutical) CMAB-304 Phase Ⅲ Shanghai CP Guojian Diffuse large B cell lymphoma Details
Ocaratuzumab AME-133; AME-133v; LY-2469298 Phase Ⅱ Applied Molecular Evolution, MENTRIK Biotech Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase Ⅰ Henan Cancer Hospital B-cell lymphoma Details
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) LZM-002,LZM002 Phase Ⅰ Livzon Group Diffuse large B cell lymphoma, CD20-positive follicular lymphoma Details
ABP-798 ABP-798; APB-798 Phase Ⅲ Amgen, Allergan Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) Details
RO-7082859 RO 7082859 Phase Ⅰ Roche Non-Hodgkin's lymphoma (NHL) Details
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) Phase Ⅱ Shanghai Longyao Biotechnology Refractory diffuse large B cell lymphoma Details
Rituximab biosimilar (Siam Bioscience) BLA Filing Siam Bioscience B-cell lymphoma Details
Anti-CD20 monoclonal antibodies (Verenium) Phase Not Specified BASF, MMRGlobal Non-Hodgkin's lymphoma (NHL) Details
Anti-CD20 monoclonal antibody (BioMedics) BM-ca Phase Ⅰ BioMedics Non-Hodgkin's lymphoma (NHL) Details
B-cell lymphoma gene therapy (City of Hope) Phase Ⅰ City of Hope National Medical Center B-cell lymphoma Details
Iodine 131 tositumomab TST/I131-TST Withdrawn GlaxoSmithKline Non-Hodgkin's lymphoma (NHL) Details
SBI-087 PF-05230895; PF-5230895; SBI-087 Phase Ⅱ Emergent, Pfizer Rheumatoid arthritis (RA) Details
Rituximab biosimilar (Chia Tai Tianqing Pharmaceutical Group) TQB-2303 Phase Ⅱ Chiatai Tianqing (CTTQ) Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Hualan Biological Engineering) WBP-263,WBP263; WBP 263 Phase Ⅲ Hualan Biological Engineering Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Genor Biopharma) GB-241,GB241; GB 241 Phase Ⅲ Genor Biopharma, Nanjing Yoko Biological Diffuse large B cell lymphoma, Non-Hodgkin's lymphoma (NHL) Details
Anti-CD3 anti-CD20 bispecific antibody (Genmab) GEN-3013 Phase Ⅱ Genmab hematological malignancies Details
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) Phase Ⅰ Fred Hutchinson Cancer Research Center, National Cancer Institute Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Burkitt's lymphoma, Non-Hodgkin B-cell lymphomas Details
Veltuzumab hA20; IMMU-106 Phase Ⅱ Immunomedics Immune thrombocytopenic purpura, Non-Hodgkin's lymphoma (NHL) Details
Ublituximab B-603; R603; LFB-R603; 1303; EMAB-6; TG-1101; TG-20; TGTX-1101; TG-1303; U59UGK3IPC (UNII code),B603,LFBR603,TG1101,TG20,TGTX1101 Phase Ⅲ TG Therapeutics, ILDONG PHARMACEUTICAL B-cell lymphoma, Chronic lymphocytic leukemia (CLL) Details
Rituximab biosimilar (Bionovis/The Instituto) Phase Not Specified Bionovis, The Instituto Vital Brazil Granulomatosis with polyangiitis, Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) Details
Rituximab biosimilar (Mabion) MabionCD-20 BLA Filing Mabion Diffuse large B cell lymphoma, Rheumatoid arthritis (RA) Details
Rituximab biosimilar(Pfizer) PF-05280586; PF-5280586,PF05280586; PF5280586; PF 05280586; PF 5280586 BLA Filing Pfizer Follicular lymphoma, Rheumatoid arthritis (RA) Details
Rituximab biosimilar (Zhejiang hisun pharmaceutical) HS-006 Phase Ⅱ Hisun Pharm Diffuse large B cell lymphoma Details

This web search service is supported by Google Inc.

totop